16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-08-21
Respondents who reported no difficulty deciding (DECIDE = 2) had substantially lower odds of SCD than those who reported difficulty (DECIDE = 1; aOR approximately 0.13; FDR < 0.05). 1 key finding →
Design: post-hoc analysis
Participants: 298,944
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-08-21
BackgroundAsymptomatic carotid artery stenosis (ACAS) increases the risk of stroke, and is associated with cognitive decline. 5 key findings →
Design: systematic review
Participants: 4,267
Evidence: high
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-08-22
BackgroundThe brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging. 2 key findings →
Design: longitudinal study
Participants: 202
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-08-25
We examined whether their metabolomic profiles also differed and whether subtype-related metabolic patterns were associated with dementia, stroke, and all-cause mortality. 5 key findings →
Participants: 7,671
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-08-25
In the fully adjusted Cox model, baseline statin exposure was associated with a lower risk of incident AMI (HR, 0.805; 95% CI, 0.731-0.887). 3 key findings →
Design: cohort study
Participants: 174,014
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-09-07
O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/26361997v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@1dac0d9org.highwire.dtl.DTLVardef@aaf8f2org.highwire.dtl.DTLVardef@be10a1org.highwire.dtl.DTLVardef@35c7be_HPS_FORMAT_FIGEXP M_FIG C_FIG BACKGROUNDThe effect of neurovascular health on cardiovascular outcomes is not well-known. 4 key findings →
Participants: 3,263
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-09-14
Higher education (OR = 1.23, SE = 0.05, 95% CI = [1.10, 1.36], p < 0.001), female sex (OR = 1.30, SE = 0.09, 95% CI = [1.10, 1.55], p = 0.003), and lower age (OR = 0.67, SE = 0.04, 95% CI = [0.61, 0.73], p < 0.001) were associated with increased odds of SuperAger status. 5 key findings →
Participants: 3,513
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-09-15
BackgroundLebanon is undergoing substantial demographic and social change, with older adults comprising approximately 10% of the population. 5 key findings →
Design: longitudinal study
Participants: 1,871
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-09-20
ObjectiveEffective strategies to prevent Alzheimers disease and related dementias (ADRD) are limited. 5 key findings →
Participants: 9,584
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-09-25
Over a median follow-up of 13 years, 5,304 participants developed dementia. 4 key findings →
Participants: 151,832
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv (preprint)
·
2026-09-26
Hearing loss is a potential risk factor for dementia, but public awareness of this link and its behavioral implications remain poorly understood. 2 key findings →
Design: cross-sectional
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
Research Square
·
2026-10-15
Alzheimer’s disease (AD) involves widespread metabolic, mitochondrial, inflammatory, and redox dysfunction. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
Preprints.org
·
2026-10-08
However, increasing evidence indicates that systemic metabolic dysfunction, chronic inflammation, intestinal dysbiosis, hepatic abnormalities, and barrier impairment may substantially influence disease susceptibility and progression. 1 key finding →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
bioRxiv
·
2026-10-05
Alzheimer’s Disease (AD) is characterised by the progressive depletion of Acetylcholine (ACh), a neurotransmitter essential for cognition and synaptic communication. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv
·
2026-09-29
Among 1,288,359 women, 20,070 with AUD were matched to 100,339 controls. 3 key findings →
Design: prospective cohort
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
Research Square
·
2026-09-24
Central Nervous System (CNS) hyperexcitability is increased during aging and also during alcohol withdrawal. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
bioRxiv
·
2026-09-03
Metabotropic glutamate receptors (mGluRs) regulate glutamatergic transmission and have been implicated in diverse neuropsychiatric disorders, but human postmortem evidence remains fragmented. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
Research Square
·
2026-09-02
The 2,885 participants had a mean age of 69.5 years. 4 key findings →
Design: longitudinal study
Participants: 2,885
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
Research Square
·
2026-08-10
Rhabdomyolysis is a common syndrome involving the breakdown of muscle tissue. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv
·
2026-08-04
Neuroticism, a personality trait characterized by the predisposition to experience intense and frequent negative emotions, has been associated with an increased risk of Alzheimer’s disease (AD). 5 key findings →
Participants: 1,277
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv
·
2026-07-27
Electronic health records linked documented glucosamine use to faster progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) and poorer survival after dementia. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
PsyArXiv
·
2026-07-23
INTRODUCTIONLittle is understood about the extent to which lifestyle factors can advance or delay the risk of developing dementia, and whether that is dependent on non-modifiable factors, e.g. sex and genetic susceptibility.METHODSAmong 224,516 UK Biobank participants aged ≥50 years at baseline, Cox regression examined the relations of apolipoprotein E gene (APOE) genotypes, and lifestyle with incident dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv
·
2026-07-16
Dementia is a progressive condition that impairs cognitive processes such as memory, decision-making, and the ability to manage daily activities. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
bioRxiv
·
2026-07-06
DMII provides a metabolomics-based framework for assessing diet-related chronic inflammation using metabolomics data. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
16/100
⚠ Preprint — not yet peer-reviewed
alzhub usefulness score 16 out of 100.
·
medRxiv
·
2025-12-02
Our findings demonstrate differential effects of nicotine on AD risk and smoking intensity on white matter integrity, requiring triangulation with complementary methodological approaches to better inform potential long-term risks of nicotine intake on neurocognitive outcomes. 3 key findings →
Design: cohort study
Participants: 334,757
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.